Can I Take St. John's Wort with Egrifta (Tesamorelin)?

What Is the Interaction Between St. John's Wort and Egrifta (Tesamorelin)?

The short answer: these two do interact, though not through the most direct route. St. John's Wort does not break down tesamorelin itself, because tesamorelin is a synthetic peptide hormone processed by proteolytic enzymes, not CYP450 enzymes. The concern is more layered than a simple pharmacokinetic clash.

St. John's Wort (Hypericum perforatum) is one of the most pharmacologically active herbal supplements on the market. Research published in Clinical Pharmacokinetics confirmed that St. John's Wort is a strong inducer of CYP3A4, CYP2C9, and P-glycoprotein, enzymes responsible for metabolizing a large portion of prescription drugs. Women with HIV are almost always on antiretroviral therapy (ART), and many ART regimens are highly CYP3A4-sensitive. When you add St. John's Wort, you risk reducing ART plasma concentrations to sub-therapeutic levels, which is a well-documented and serious concern.

Because tesamorelin is prescribed specifically for people living with HIV who are on ART, the interaction picture is not just "tesamorelin plus St. John's Wort." It is the triangle of tesamorelin, your ART, and St. John's Wort that creates the actual clinical risk.

How St. John's Wort Affects CYP3A4

The active component in St. John's Wort responsible for enzyme induction is hyperforin. A study in the Journal of Pharmacology and Experimental Therapeutics found that hyperforin activates the pregnane X receptor (PXR), which then upregulates CYP3A4 gene expression in the liver and intestinal wall. The result is faster breakdown of CYP3A4 substrates, meaning lower drug blood levels for the same dose.

This is not a minor or theoretical effect. The FDA has published a safety communication noting that St. John's Wort can reduce plasma concentrations of CYP3A4 substrates by 40 to 70 percent in some cases. For antiretrovirals like indinavir, a 57 percent reduction in AUC was documented in a pharmacokinetic study.

How Tesamorelin Itself Is Processed

Tesamorelin is a modified analog of growth-hormone-releasing hormone (GHRH). After subcutaneous injection, it binds pituitary GHRH receptors and triggers growth hormone (GH) secretion. GH then stimulates the liver to produce insulin-like growth factor-1 (IGF-1). The FDA label for Egrifta SV states that tesamorelin is cleaved by endogenous proteases, not by hepatic CYP enzymes. Its half-life is approximately 26 minutes.

So the direct pharmacokinetic route, St. John's Wort degrading tesamorelin in the liver, does not apply. The indirect routes are what matter.

The Real Risk: Your Antiretroviral Regimen

Most women prescribed Egrifta are also taking a protease inhibitor, an integrase strand transfer inhibitor, or a non-nucleoside reverse transcriptase inhibitor. Several of these are CYP3A4 substrates or inhibitors.

The U.S. Department of Health and Human Services HIV treatment guidelines explicitly list St. John's Wort as contraindicated with most protease inhibitors and NNRTIs because of clinically significant induction of their metabolism. If your ART levels drop, you risk viral rebound, resistance mutations, and treatment failure. Tesamorelin controls lipodystrophy only as long as your HIV is adequately suppressed with effective ART.

Which ART Drugs Are Most Vulnerable

• Ritonavir and ritonavir-boosted regimens (lopinavir, darunavir, atazanavir): strong CYP3A4 substrates
• Rilpivirine: a pharmacokinetic study in Antimicrobial Agents and Chemotherapy showed St. John's Wort reduced rilpivirine AUC by 50 percent, enough to cause virologic failure
• Efavirenz: already a CYP3A4 inducer; adding St. John's Wort compounds induction unpredictably
• Elvitegravir/cobicistat: cobicistat is a CYP3A4 inhibitor and is itself a CYP3A4 substrate; St. John's Wort can destabilize this combination

The clinical bottom line is this: St. John's Wort poses a direct threat to the ART backbone that makes tesamorelin therapy feasible and meaningful.

Pharmacodynamic Interaction: Cortisol, GH, and Mood

There is a second, less-discussed angle. St. John's Wort affects the hypothalamic-pituitary axis through serotonergic, dopaminergic, and noradrenergic mechanisms. A review in Pharmacopsychiatry documented that St. John's Wort modulates cortisol response in humans. Cortisol is a known inhibitor of GH secretion. Elevated or dysregulated cortisol can blunt the pituitary's response to GHRH, the very receptor that tesamorelin targets.

If St. John's Wort alters your cortisol rhythm or HPA axis tone, it may reduce the GH-stimulating effect of tesamorelin, lowering IGF-1 production and diminishing the visceral fat reduction you are trying to achieve. This is a pharmacodynamic interaction, meaning it involves competing actions on the same physiological pathway, not drug metabolism. It is harder to measure but still clinically real.

Why This Matters More for Women

Women have different basal GH secretion patterns than men. A study published in the Journal of Clinical Endocrinology and Metabolism found that women secrete GH in more frequent pulses and at higher overall amplitude compared to men, with estrogen playing a direct stimulatory role on pituitary somatotroph cells. Perimenopausal and postmenopausal women see GH pulse amplitude decline as estrogen falls. If St. John's Wort further disrupts HPA axis regulation in a woman whose GH axis is already estrogen-depleted, the combined suppression of tesamorelin's effect may be more pronounced than in a male patient.

This sex-specific difference in GH physiology has not been studied directly in the context of St. John's Wort plus tesamorelin. The evidence is extrapolated from separate bodies of literature. The data gap is real, and we flag it here because women deserve to know when the clinical picture involves informed inference rather than direct trial data.

The WomanRx framework for assessing this combination across life stages:

| Life Stage | Primary Concern | Action | |---|---|---| | Reproductive years (on ART) | ART efficacy and contraceptive failure from CYP3A4 induction | Avoid St. John's Wort entirely | | Trying to conceive | Tesamorelin is contraindicated; stop before conception | Discuss ART and supplement plan with prescriber | | Perimenopause | Declining estrogen reduces GH axis reserve; pharmacodynamic blunting is plausible | Avoid combination; monitor IGF-1 closely | | Post-menopause | Same GH axis concern; also higher cardiovascular risk if lipodystrophy is uncontrolled | Avoid; prioritize ART stability |

Pregnancy and Lactation: Tesamorelin Is Contraindicated

This section is required reading if there is any chance you could become pregnant.

Pregnancy

Tesamorelin is classified as FDA Pregnancy Category X. Animal reproduction studies showed fetal harm, and the drug has no established indication in pregnancy. If you become pregnant while taking Egrifta, stop the drug and contact your prescriber immediately. Visceral fat redistribution, while distressing, does not outweigh fetal risk.

St. John's Wort's safety in pregnancy is also poorly characterized. A systematic review in BJOG found insufficient controlled human data to establish safety and noted theoretical concerns about uterotonic effects. Given the absence of safety data and the established risks of tesamorelin, neither agent should be used during pregnancy.

Contraception Requirement: This Is Not Optional

Women of reproductive age taking tesamorelin must use effective contraception. The CYP3A4-inducing effect of St. John's Wort directly threatens hormonal contraceptive efficacy. ACOG Practice Bulletin guidance on contraception recognizes enzyme inducers as a drug class that reduces the plasma levels of ethinyl estradiol and progestins in combined hormonal pills, patches, and vaginal rings.

If you are on tesamorelin for HIV-associated lipodystrophy and you add St. John's Wort, you may inadvertently reduce your hormonal contraceptive to sub-therapeutic levels. This creates a pregnancy risk while you are on a Category X drug. The consequences of unintended pregnancy on tesamorelin are serious.

Recommended contraceptive options if you must use a CYP3A4 inducer (or if your ART already includes one): copper IUD or levonorgestrel IUD, which are not affected by enzyme induction; or depot medroxyprogesterone acetate with your prescriber's guidance.

Lactation

No human lactation data exist for tesamorelin. The FDA label advises against use in breastfeeding women. Growth hormone peptides have some transfer potential through breast milk, and the impact on a nursing infant's GH axis is unknown. St. John's Wort does transfer into breast milk; a study in Breastfeeding Medicine found that infant exposure occurred and noted case reports of infant colic and lethargy. Neither agent is recommended during lactation.

Women-Specific Conditions Tesamorelin Touches

Tesamorelin's approval is narrow: HIV-associated lipodystrophy only. But the hormone pathway it activates (GH/IGF-1) touches several conditions that disproportionately affect women.

PCOS and IGF-1

Women with polycystic ovary syndrome already have elevated IGF-1 activity in many cases, contributing to hyperandrogenism and anovulation. A study in Fertility and Sterility found that IGF-1 amplifies LH-stimulated androgen production in thecal cells. Artificially raising IGF-1 with tesamorelin in a woman with PCOS could theoretically worsen androgen excess, though tesamorelin is not used for PCOS and this is an off-label and unstudied concern.

Metabolic Health and HIV-Positive Women

Data from the Women's Interagency HIV Study (WIHS) show that HIV-positive women have higher rates of visceral adiposity, insulin resistance, and cardiometabolic risk compared to HIV-negative women of the same age, even on stable ART. Tesamorelin reduced visceral adipose tissue by approximately 18 percent in the LBCL-1 and LBCL-2 trials, which enrolled predominantly male participants. Women were underrepresented. The sex-specific efficacy and safety profile in women has not been fully characterized in dedicated trials.

Bone Health

GH and IGF-1 support bone mineral density. HIV-positive women already carry excess fracture risk from ART-related bone loss (especially with tenofovir disoproxil fumarate), chronic inflammation, and low vitamin D. Tesamorelin's anabolic effect on bone through IGF-1 may offer some benefit, but no fracture-endpoint data in women exist. St. John's Wort does not have established effects on bone metabolism, though its CYP3A4 induction could theoretically reduce vitamin D availability by accelerating its hepatic conversion.

Who This Is Right For, and Who Should Reconsider

Women Who Are Appropriate Candidates for Tesamorelin

• Adult women with HIV on stable ART who have confirmed excess visceral adiposity on imaging
• Women who have failed dietary and exercise interventions for HIV-related lipodystrophy
• Women with a normal or mildly elevated IGF-1 at baseline (the FDA label recommends checking IGF-1 before starting)
• Women not pregnant, not planning pregnancy, and using reliable non-hormonal or enzyme-induction-resistant contraception

Women Who Should Not Take This Combination (Tesamorelin Plus St. John's Wort)

• Women on any protease inhibitor or NNRTI-based ART: the ART interaction risk is severe
• Women using hormonal contraception: St. John's Wort may render it ineffective
• Women with active malignancy: tesamorelin is contraindicated; IGF-1 elevation may be harmful
• Perimenopausal or postmenopausal women with suspected HPA axis dysregulation: pharmacodynamic blunting of GH response is plausible
• Pregnant or breastfeeding women: neither drug is safe in these settings

Women Who Often Take St. John's Wort and May Not Know the Risks

St. John's Wort is the most commonly used herbal antidepressant in the United States. A JAMA survey of supplement use in people with HIV found that more than 60 percent of people with HIV used at least one herbal supplement, and many did not disclose this to their prescribers. Women with HIV are also at higher rates of depression and anxiety than the general population. The impulse to reach for St. John's Wort for mood support while managing a complex chronic illness is understandable.

But the drug interaction profile of St. John's Wort in the HIV setting is one of the most dangerous in all of herbal medicine. A landmark case report in The Lancet documented subtherapeutic indinavir levels and HIV viral rebound in patients who added St. John's Wort to their ART. This is not a theoretical warning.

If you are managing depression or mood alongside HIV and lipodystrophy, SSRIs, SNRIs, or referral to a mental health specialist are safer routes, and your telehealth prescriber can help coordinate that care.

Monitoring If You Are Already Taking Both

If you are currently taking Egrifta and have been using St. John's Wort without realizing the risk, here is what to do:

1. Do not abruptly stop St. John's Wort without telling your prescriber. Stopping a serotonergic supplement suddenly may cause mood discontinuation symptoms.
2. Contact your prescriber today. Your HIV viral load and ART drug levels should be checked promptly.
3. Ask for an IGF-1 level. If St. John's Wort has blunted tesamorelin's GH stimulation, your IGF-1 may be lower than expected. The Egrifta SV prescribing information recommends IGF-1 monitoring every six months, but an unscheduled check is warranted here.
4. Review your contraception. If you were using combined hormonal contraception, consider emergency contraception if there is any chance of unprotected sex in the past few weeks, and switch to a non-hormonal method immediately.
5. Taper St. John's Wort under medical supervision. Your prescriber may want to recheck ART drug levels two to four weeks after discontinuation, since CYP3A4 induction takes time to reverse, typically two to four weeks after stopping the inducer.

Dose Separation: Does Timing the Doses Help?

No. Dose separation does not resolve this interaction. CYP3A4 induction by St. John's Wort is a gene-expression-level effect: the enzyme is upregulated in the liver and intestinal wall continuously for as long as you are taking the supplement. Taking tesamorelin four hours before or after St. John's Wort does not change the induction state. The only solution is discontinuing St. John's Wort.

What the Evidence Gap Means for You

The honest summary of the clinical literature: there is no published trial that directly examined the interaction between tesamorelin and St. John's Wort. The concern is constructed from:

• The well-documented CYP3A4 induction by St. John's Wort
• The CYP3A4 sensitivity of most ART regimens used alongside tesamorelin
• The pharmacodynamic overlap between St. John's Wort's HPA axis effects and tesamorelin's GH axis mechanism
• The contraceptive safety concern specific to women

Women have been historically underrepresented in both HIV pharmacokinetic studies and in drug-herb interaction trials. The recommendations here are clinically grounded but partially extrapolated from male-dominant data sets. Your prescriber should treat you as an individual and account for your specific ART regimen, your menopausal status, your contraceptive method, and your mood-management needs.

Your prescriber at WomanRx can review your full medication and supplement list and recommend a safer alternative for mood support. St. John's Wort is not worth the risk to your ART efficacy, your tesamorelin outcomes, or your contraceptive protection.